Abstract
Mental health disorder (MHD) incidence rates continue to rise, contributing significantly to the global disease burden. While their aetiology was once thought to be strictly genetic or environmental, the study of epigenetics has reshaped our understanding of their underlying mechanisms. Environmental exposures are understood as key players in the development of MHDs. Growing research has elucidated the critical role of environmental chemical exposures—particularly through endocrine-disrupting chemicals and heavy metals—in influencing MHD incidence through epigenetic mechanisms (i.e. DNA methylation, histone modification and non-coding RNA action). A key breakthrough in this field is the recognition that epigenetic modifications are not necessarily permanent. By exploiting the potential reversibility of DNA methylation and histone modification, new avenues for therapeutic interventions open, in which normal gene function could be restored. Understanding and harnessing epigenetic reversibility not only provides hope for novel and personalized treatment strategies but also underscores the importance of environmental protection policies in mental health prevention.
Keywords: epigenetics, mental illness, personalized medicine
Introduction
Mental health disorders (MHDs) are a leading cause of disability worldwide and contribute significantly to the global disease burden [1], ranking among the top 10 diseases globally. Individuals with severe mental illnesses have notably shorter life expectancies, often dying 10–20 years earlier than the general population [2,3]. Comorbidities among MHDs are common [4,5], with major depressive disorder (MDD) and generalized anxiety disorder (GAD) among the most frequent [6]. Such co-occurrences pose a diagnostic challenge, as symptoms like insomnia, difficulty concentrating, fatigue and agitation often overlap among multiple disorders, thus complicating the development of effective treatment plans [7]. Additionally, those who struggle with comorbid mental health conditions tend to have higher severity of illness, lower responses to treatments and interventions, poorer prognosis, lower quality of life and generally place more strain on the healthcare system [5,6]. However, these comorbidities extend beyond just GAD, with MDD frequently co-occurring with a range of other psychiatric conditions, such as post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), eating disorders and substance use disorders [6,8]. Therefore, comorbidities present a significant challenge to both diagnosis and treatment, as symptoms intersect and interplay, which overall complicates the process. This highlights the importance of determining the underlying aetiology in order to identify the most effective treatment strategies.
While there has been a significant expansion of knowledge on MHDs, the causal mechanisms of psychiatric disorders remain largely elusive [9]. Early research on MHDs often focussed on identifying single genetic causes; however, advances in genetics have revealed a more nuanced understanding of heritability across disorders [9]. Genetic influence on MHDs is now largely described as a gradient, with more severe and less common disorders (e.g. autism, schizophrenia, bipolar disorder) contributing higher estimates of heritability, while more common and less severe disorders (e.g. anxiety, MDD) are associated with lower degrees of heritability [9,10]. Some argue that severe mental illnesses are a result of several genetic loci, while others dispute that they are rather associated with single genes [9]. However, most genetic variants that contribute to MHDs act in unison and are common occurrences [11]. Thus, every individual has a general genetic risk to a psychiatric disorder [11]. While genetic analysis has made significant strides in demonstrating its influence on MHDs, there are certain aspects of their development that are incongruent with a genetic explanation alone. For instance, multiple epidemiological studies have highlighted a strong association between low socioeconomic status and the occurrence of MHDs in children [12]. These relationships, which fall outside the scope of genetic explanations, underscore the importance of understanding environmental factors playing a causal role in the onset of mental health conditions.
Epigenetics and environmental exposures
These previously unexplainable relationships can now be better understood through the lens of epigenetics. Once dominated by the nature vs. nurture debate, discourse surrounding MHDs has evolved to recognize that genetics and environment are not mutually exclusive. Rather, both interact in shaping the development and trajectory of phenotypes in general, including MHDs. This emphasizes the pivotal role of epigenetics in this dynamic and nuanced interplay [11]. Through processes such as DNA methylation, histone modification and non-coding RNA action, the chromatin state is altered, thereby influencing gene activation. Moreover, epigenetic modifications can respond to environmental exposures [13]. DNA methylation typically silences genes by adding methyl groups to cytosine bases neighbouring guanines; chemical modifications in histone tails can either loosen or tighten DNA winding around histones, affecting accessibility to transcription factors; and non-coding RNAs can interfere with transcription or translation processes [14]. Epigenetic patterns are established during crucial developmental periods in a cell type specific manner, molding tissue specific gene expression diversity.
Recognition of the profound impact of early life conditions on shaping health and disease risk has become widely acknowledged and increasingly emphasized, aligning with the principles of the Developmental Origins of Health and Disease (DOHaD) theory [12]. This well-established framework explains how the prenatal period, along with early-life environments and events, can result in the alteration of developmental trajectories [15]. These modifications may have lasting effects, influencing chronic health outcomes and disease susceptibility throughout the lifespan [15]. Thus, the origins and progression of MHDs can be further explained through the lens of DOHaD, with the ‘exposome’ representing the totality of early exposures and experiences during life [15]. Environmental exposures within the DOHaD theory include, but are not limited to, chemical and pharmacological, chronic stress and trauma, obesity and malnutrition, and other determinants of health during early life [15]. These environmental exposures have been studied extensively to understand their role in shaping MHDs.
Early life exposures and MHDs
Growing amounts of empirical data suggest adverse childhood experiences (ACEs) increase the risk of MHDs, specifically MDD, PTSD, borderline personality disorder (BPD), GAD, suicidal ideation and dissociative symptoms [16–20]. Importantly, the risk of developing an MHD (specifically MDD), as well as their severity, is suggested to be dependent on the type of ACE. Furthermore, ACEs can act in single or clustered events, with the latter increasing severity [16,21]. ACEs predominantly associated with an increased risk of MHDs include sexual and physical abuse, childhood neglect, household dysfunction (such as parental psychiatric morbidity), as well as extreme traumatic shock (such as parental death) [16,17,21–24]. Thus, numerous ACEs have been shown to play a causal role in the incidence of MHDs throughout an individual’s lifetime. Importantly, these adverse experiences often coincide with different chemical exposures, which can exacerbate their impact on mental health outcomes. For instance, children living in impoverished communities often face disproportionate rates of chemical exposures, such as to lead or endocrine-disrupting chemicals (EDCs), which can hinder development and amplify the risks of MHDs [25].
Recent research highlights the potential link between early-child nutritional habits and MHDs, specifically obesity. Obesity has consequential impacts in children and adolescents on both physical health, mental health and quality of life. As the prevalence of childhood obesity has risen dramatically, so too has the need to better understand its impact not only on physical health, but also on the development of MHDs [26]. Research has found that overweight children experience difficulties with body image, bullying, peer-peer relationships, lower self-esteem and self-perception, lower school performance and lower health-related quality of life (HRQoL), all of which are risk factors for developing MHDs in adolescence or in adulthood [26–31]. Additionally, psychiatric comorbidities within childhood obesity are vast, including a range of mood and anxiety disorders, substance use, as well as somatoform and eating disorders [32]. Thus, connections can be drawn between childhood obesity and the increased risk of developing MHDs. In parallel, researchers have theorized how certain environmental chemical exposures can induce obesity. These are known as obesogens, which act at critical developmental periods, causing metabolic disturbances and increasing obesity susceptibility [33–35]. There are several different major classes and sources of obesogens: bisphenols, phthalates, parabens, non-steroid oestrogens, brominated flame retardants, polychlorinated biphenyls, organotins, all of which, upon exposure at work, home or through the environment, increase the risk of obesity. Importantly, exposure to obesogens may in turn heighten the risk of developing a MHD [34].
The DOHaD framework now extends to environmental exposures to maternal prescribed medications, psychotropic substances, stimulant drugs or alcohol prenatally or during early life. Individuals exposed to these compounds have heightened risk for both developmental disorders and MHDs [36–39], specifically those related to mood, anxiety and behavioural disorders [40]. Of those listed, foetal alcohol spectrum disorder remains the most studied, with heavy prenatal alcohol exposure meeting the criteria for at least one psychiatric disorder, namely MDD, BPD, GAD and substance use disorders [39,41,42]. As both addictive and essential drug use during pregnancy rises, so too has the awareness of its detrimental effects on fetuses, such as neurodevelopmental delays, poor physical health and, notably, an increased risk of MHDs [38,43]. Importantly, children prenatally affected by addictive drugs are also more likely to experience additional risk factors when a parent has a substance use disorder. These risk factors include poverty, parental co-morbidities, household dysfunction and poor overall health, all of which can indirectly contribute to the incidence of MHDs [38,43].
In addition to the effects observed during lifetime, recent research has uncovered effects of environmental exposures on behaviour across generations. One study that exemplifies this phenomenon examined the inheritance of parental trauma in offspring [44]. They exposed F0 mice to a fear-conditioning odour before conception and discovered that conceived F1 and F2 generations had increased behavioural sensitivity to the F0-conditioned odour, but not to other odours [44]. DNA methylation changes were found in olfactory receptor genes in the sperm of the F0 and F1 generations, highlighting that the transmission of the behavioural effects across generations may be mediated by germ line epigenetic alterations [44]. Another study examined microRNA (miRNA) expression in mice and its progeny upon exposure to traumatic stress in early life [45]. Researchers found that traumatic experiences in early life led to the alterations of miRNA in the serum, brain and sperm of traumatized mice and their progenies. Injecting sperm RNAs from traumatized males into wildtype oocytes reproduced the behavioural and metabolic alterations in resulting offspring [45]. Together, these studies exemplify an important area in the study of epigenetics, displaying how epigenetic modifications can help explain the molecular mechanisms involved in the transgenerational transmission of traumatic events.
Different sources of environmental chemical exposures
The consequences of environmental chemical exposures on the etiology of a variety of diseases and conditions—including cancer, premature birth, infertility and neurodevelopmental disorders—are well documented, particularly due to their roles in endocrine disruption and neurotoxicity [46–48]. However, their influence on MHD incident rates remains less understood.
Endocrine-disrupting chemicals
EDCs are a large class of exogenous chemicals that interfere with any hormone action through various mechanisms: disruption of hormone synthesis, transport or breakdown, alteration of the development of hormone receptors, modification of hormone binding, or action as hormone antagonists [46,48–50]. Many environmental EDCs are released to the environment during manufacturing, production and use of synthetic man-made materials like pesticides, plastics, flame-retardants, metals, food additives and personal care products [46,48,49]. Particularly, there are growing concerns around the influence that EDC exposures, especially in early life, have on MHD outcomes and incident rates, as EDC effects are now far reaching [51].
Although EDCs encompass approximately 85,000 chemical compounds of different types, only 1000 are recognized and understood as having endocrine-disrupting properties [52,53]. These include, but are not limited to, phenols (bisphenol A [BPA] and its analogues), phthalates, pre- and polyfluoroalkyl substances (PFASs), polycyclic aromatic hydrocarbons (PAHs), alkylphenols, brominated flame retardants, halogenated aromatics and pesticides [48]. The links between various EDCs and internalizing psychiatric symptoms (ex. anxiety, depression and somatisation) or externalizing psychiatric symptoms (ex. aggression, hyperactivity and conduct problems), as well as MDD, have become increasingly evident [48,52,54–57]. Certain EDCs have been shown to disrupt and dysregulate the hypothalamic-pituitary-adrenal and the hypothalamic–pituitary–gonadal axes, both of which are critical for neuronal processes and mental health [55,58]. Such disruption can impair stress regulation, hormone balance and brain development, contributing to mood disorders, cognitive impairments and other neuropsychological conditions [55,58].
Even at low doses, EDCs can influence bodily systems, sometimes with impacts only observed later in life [48]. Epigenetic markers such as DNA methylation can potentially aid in the explanation of latency in neurobehavioural disorders upon EDC exposure [53]. Additionally, DNA methylation changes resulting from EDC action have been implicated in the aetiology of neurological disorders and MHDs, especially when occurring on genes involved in serotonin and dopamine pathways [59,60]. For example, one study exposed adolescent male rats to chlorpyrifos , an organophosphorus pesticide, and then subjected the rats to a variety of emotional behavioural tests related to serotonergic function [61]. Researchers found that repeated exposure to chlorpyrifos led to alterations of emotional behaviours related to serotonergic system [61]. One way that EDCs can impact DNA methylation is by altering the expression of DNA methyltransferases (DNMT), enzymes that add methyl groups to cytosines neighbouring guanines (CpGs). It is hypothesized that EDC action on DNMT expression is a main driver of downstream epigenetic and cellular changes [14]. Kundakovic et al. showed that BPA exposure altered mRNA levels of DNMT1, DNMT3A and oestrogen receptors in the cortex and hypothalamus of mice, leading to social and anxiety-like behaviour [62,63]. Even at low dose exposure during early life, EDCs can cause incomplete and impaired methylation of specific gene regions, hindering hippocampal neurogenesis and overall brain function, thus bestowing greater susceptibility to neuronal disorders such as MDD [55,59]. Many EDCs are small, lipophilic compounds, rendering them the ability to diffuse through membranes and even cross the blood-brain barrier [55,64]. Thus, EDCs can act on various receptors, although its influence on the nuclear receptor family (e.g. oestrogen receptors, androgen receptors and thyroid hormone receptors) is the most studied mode of action [14]. Additionally, agonistic or antagonistic EDC action on the aryl hydrocarbon receptor has gained recognition, as its activation by persistent organic pollutants (POP), such as pesticides, regulates gene transcription and expression in a similar way as nuclear receptors [14,65–67]. POP exposure during early life can cause improper brain formation and behavioural or cognitive defects, mediated through aryl hydrocarbon receptor [59]; this is exemplified in individuals working in environments contaminated with pesticides (e.g. chlorpyrifos, paraquat) and polychlorinated biphenyls, who exhibit symptoms of depression and anxiety, as well as learning deficits and memory dysfunction [59,68]. In addition to DNA methylation, EDC exposure can alter other epigenetic mechanisms, such as histone-modifying enzyme activity [14,69,70]. For example, upon exposure to the pesticide TDCC, the activity of histone methyltransferases can be amplified, thus modifying the epigenetic status, with cellular consequences that impact pathology [65]. Recent data have also shown that EDC exposure can alter miRNA expression, cumulatively contributing to the array of epigenetic modifications involved in the development of depression [59,64,71].
EDCs impact on neurodevelopment and other neurological processes occur primarily through changes in its monoaminergic transmission [59,72,73]. EDCs (e.g. BPA) affect this system, as well as the mesolimbic dopamine pathway, via the disruption of dopamine synthesis, release and turnover, which impacts its transport and expression upon receptor binding [59,70,74–76]. Consequently, EDC exposure would increase depression incidents due to the alterations in neurotransmitter systems [59,61]. Importantly, environmental chemical exposures rarely occur in isolation but rather in an intertwined complex system where multiple different exposures happen simultaneously [40]. These cocktails of exposures are pervasive, ubiquitous and continuously impact our mental health, contributing to the onset of symptoms or diagnoses of MHDs.
Heavy metals
The relationship between early-life exposure and the toxic effects of heavy metals on neurodevelopmental outcomes is well established and known to contribute to intellectual disabilities, autism spectrum disorder (ASD), learning difficulties and modest IQ reductions [40,77]. Heavy metals are widespread chemical contaminants that can be extremely toxic to several organ systems and are associated with pathologies such as cancer, cardiovascular, neurological and autoimmune diseases [40,78]. As epidemiological and clinical studies continue to grow, the links between heavy metals and MHDs become more established [40,77]. Research has signalled that heavy metal exposure, such as lead, cadmium, manganese, arsenic and zinc, is associated with various mental illnesses, including depression, anxiety, cognitive dysfunction, mood disorders, bipolar disorder and schizophrenia [79–81]. Blood lead concentrations in children have declined substantially worldwide, dropping from 15 µg/dl in 1970 to approximately 2.0 µg/dl by the late 1990s [82]. However, average levels of lead and other heavy metals vary across countries, largely influenced by differences in regulatory frameworks, waste management practices and infrastructure [82]. Notably, even blood lead concentrations below 5 µg/dl have been associated with reductions in IQ, as well as increased risks of behavioural disorders and emotional dysregulation [82–84]. One study applied a posterior predictive distribution to assess cord blood heavy metals in relation to ASD and identified threshold levels of exposure that can predict future ASD incidence [85]. Thus, heavy metals can act as biomarkers that predict neurodevelopmental disorders such as ASD, galvanizing researchers to investigate whether heavy metals like lead or cadmium can become additional biomarkers in the diagnosis of psychiatric disorders.
The toxic action of heavy metals on the brain is unique albeit concerning, as it can damage the blood–brain barrier, reduce neuronal plasticity, induce oxidative stress and neuroinflammation, and importantly, modify gene expression patterns leading to increased vulnerability to MHDs [40]. Metal ions like lead and cadmium can generate reactive oxygen species , which is hypothesized to be one of the main drivers of epigenetic alterations upon heavy metal exposure [78,80,86]. These reactive oxygen species accumulate and can affect epigenetic markers in different ways, for example, by interfering with the ability of methyltransferases to interact with DNA [78,86] or by silencing DNA repair and tumour-suppressor genes [87]. It has been reported that arsenic, nickel, chromium, cadmium and methylmercury modify the DNA methylation status of a variety of genes [78,87–90]. Additionally, arsenic, nickel, chromium, methylmercury and copper have been shown to elicit changes in histone modifications, while arsenic, aluminium and cadmium are reported to impact non-coding RNA expression [78,87–89]. In parallel, epigenetic research on depression has demonstrated abnormal DNA methylation patterns related to neurotransmission, particularly in serotonin and dopamine pathways [60], while highlighting the roles of histone modifications and non-coding RNA action [78,86] in synaptic adaptability and stress response [60]. Together, these mechanisms play a crucial role in shaping MHD outcomes; understanding their patterns and functions could position epigenetic modifications as potential therapeutic targets.
The potential of epigenetic reversibility
Epigenetic changes can be small, potentially cumulative and may develop over time. One example of this is epigenetic clocks, which is a prediction model that approximates the chronological age of different tissues and cell types with high accuracy [91]. Epigenetic clocks measure the cumulative effects of an epigenetic maintenance system by quantifying DNA methylation at specific CpG sites [91]. Environmental exposures such as organochloride pesticide and benzene, trichlorethylene and tobacco smoke exposure have been associated with greater epigenetic age acceleration, as these exposures have altered DNA methylation patterns that develop over time [92,93]. Different levels of epigenetic regulation can interact in a dynamic, intricate and interconnected way that has the potential to generate a self-reinforcing cycle of epigenetic events.
Currently, there are ongoing discussions about how permanent epigenetic changes are, as well as their potential to be reverted when associated with diseases. Speculation surrounding the potential reversibility of aberrant epigenetic modifications is only rudimentarily understood, warranting new research to explore this. Over two decades ago, the rousing publication from biologists Ringrose and Paro, ‘Remembering Silence’, prompted conversations that questioned the ability of epigenetic modifications to return to their silenced state [94]. If one was exposed to a traumatic event and thus acquired a pathological epigenetic modification, could they ultimately rid themselves of this modification? Although ‘Remembering Silence’ pertained to epigenetic traits following a traumatic event, the same question resides following environmental chemical exposures.
The reversibility of epigenetic modifications presents exciting and novel avenues for personalized medicine in MHD treatments, potentially offering respite to individuals with MHD influenced by environmental chemical exposures—either by targeting the specific epigenetic modifications, or instead tailoring treatment strategies based on the distinct epigenetic profiles (Figure 1). This is particularly relevant when considering that the brain’s susceptibility to epigenetic modifications—such as the dynamic processes of DNA methylation [95] and histone modifications [96–98]—plays a key role in neuronal plasticity and its stress response pathways to the environment [60,95]. Unique variations in epigenetic patterns can provide opportunities for personalized treatment that targets genes associated with plasticity and synaptic activity [60]. If tissue-specific epigenetic modifications (e.g. DNA methylation) can be reversed to pre-exposure levels, either through pharmacological or non-pharmacological interventions, or removal of pathology-causing exposures, significant breakthroughs in treatment options for individuals with MHDs can occur.
Figure 1. Schematic overview depicting how environmental exposures can cause epigenetic alterations through the action of DNA methylation, non-coding RNA action and histone modification, leading to an increase in mental health disorder incidence. The potential for these epigenetic modifications to be largely reversed can be exploited to alleviate mental health disorder burden and symptoms. This reversibility can provide new avenues for therapeutics and tools for policymakers. The * represents an environmental chemical exposure. Created in (95,113 ) .
Despite the potential of epigenetic reversibility for personalized medicine in psychiatric disorders, not much is known about its mechanism. Studies in lab animals have shown that reversibility is possible. For example, a study showed that DNA methylation changes associated with smoking were largely reversed after cessation [99]. Another study assessing epigenetic modifications in response to heavy metal exposures found that removing nickel treatment led to the re-expression of a nickel-silenced gene [87]. Overall, these studies highlight the potential for similar reversibility in other exposure-related epigenetic changes. However, although reversibility is possible, the developmental time in which exposures take place plays an important role in the ability of epigenetic changes to be preserved or reversed. For instance, in mice hippocampus, one study found that DNA methylation changes were reversible in early life but became fixed and irreversible in adult life [100], suggesting that early-life environment is impactful on adult brain methylation pattern [101].
Epigenetic changes have also been shown to respond not only to chemical exposures but also to behavioural interventions. Kripalani et al. [102] examined DNA methylation changes after mind–body therapies such as meditation, yoga and tai-chi, and found that DNA methylation was lower in those who participated in mind–body therapies compared with those who did not, explaining the potential for DNA methylation patterns to decrease, and thus reverse in later life if one engages in positive behavioural experiences. Similarly, a different study employed a one-week intensive resident group program for adolescents who experienced multiple ACE that included mindfulness training, artistic expression and EMDR group therapy. A decrease in PTSD-related symptoms and changes in DNA methylation levels was found to correlate with improvements in trauma-related psychological measures [103]. Besides changes in DNA methylation triggered by behavioural interventions, epigenetic manipulations can also change behaviour. For example, one study found that by inhibiting histone deacetylase, the effects of chronic social defeat stress in mice were reversed, reducing histone-H3 acetylation and exhibiting actions similar to the antidepressant fluoxetine [101,104]. Together, these findings suggest that targeted interventions can modulate epigenetic patterns, indicating the potential reversibility that these consequential epigenetic modifications have on behaviour, offering new approaches to therapeutics.
Some drugs utilized to treat psychiatric disorders are known to have an epigenetic effect [105], highlighting the concept of epigenetic reversibility in a therapeutical context. This opens the possibility to create novel drugs that target epigenetic modifications that are known to associate with behavioural phenotypes. The emerging field of epigenetic therapeutics suggests that designing treatments specifically aimed at reversing epigenetic changes associated with detrimental outcomes may be possible, resulting in more efficient treatment alternatives. Epidrugs—a growing class of drugs designed to selectively modify the epigenetic landscape—target aberrant epigenetic modifications by inhibiting or reprogramming dysregulated epigenetic enzymes [106,107]. Initially developed for cancer therapy [106], epidrugs are now being investigated as potential treatments for central nervous system disorders, including MHDs [107]. For instance, epidrugs can be utilized as potential antidepressants to exploit the reversibility of abnormal epigenetic modifications associated with depression [60,108]. Epidrugs, such as DMNT inhibitors or histone deacetylase inhibitors, have shown therapeutic potential but may also produce off-target effects, disrupting the homeostatic function of healthy cells and causing adverse effects [109,110]. To minimize these off-target toxicities while enhancing specificity and efficacy, researchers have been investigating novel delivery mechanisms and exploring epigenetic biomarkers to support the screening, diagnosis and development of these targeted treatments [110]. Currently, FDA-approved epidrugs are used in combination with histone deacetylase inhibitors, with most clinical success and approved applications seen in the treatment of haematological malignancies [111]. For example, the FDA-approved drug Decitabine is a methyltransferase inhibitor that, along with other functions, targets DNA methyltransferase 1 to treat myelodysplastic syndrome and acute myeloid leukaemia [112]. If correctly targeted, epidrugs could modulate epigenetic marks associated with chronic stress, neuroinflammation and synaptic plasticity, potentially reverting abnormal epigenetic patterns linked to MHDs and alleviating its associated symptoms [60].
Not only could epigenetic reversibility significantly influence patient treatment plans, but it could also positively impact policy. If certain chemical-induced epigenetic changes can be reversed upon exposure removal, this can inform policy makers, as well as the public's opinion, and can also garner additional legitimacy to policy makers when building their cases to address these problems [113]. Recognizing the epigenetic impact of pollutants, endocrine disruptors and heavy metals strengthens the case for stricter regulations on hazardous substances, thus reducing public health risks.
Understanding these reversible changes can empower and offer hope to individuals by enabling targeted interventions and developing selective pharmacological agents that modify these epigenetic changes. One aspect would be to employ these therapies in patients showing treatment resistance, as it has been suggested that epigenetic changes contribute to this [95,114]. Exploiting the reversibility of epigenetic modifications could not only improve patient outcomes for MHDs associated with environmental chemical exposures but also reinforces the importance of reducing these exposures through both medical and policy-driven approaches.
Summary points.
Environmental exposures in early life, such as adverse childhood experiences, child obesity and pharmacological and non-pharmacological substances, are impactful in the onset and aetiology of mental health disorders (MHDs) in later life.
Knowledge about environmental chemical exposures, which includes endocrine-disrupting chemicals and heavy metals, continues to grow as it illustrates its negative effects exerted on the body. The epigenetic mechanisms of these environmental chemical exposures can, in part, aid in describing its contribution to increased MHD incidence rates.
The ability for epigenetic mechanisms, particularly DNA methylation, to be reversed remained largely elusive. Several studies have described the potential for DNA methylation patterns to decrease or reverse altogether upon cessation of stimulus or positive experiences. Epigenetic reversibility provides new avenues for targeted therapeutics and environmental policy.
Abbreviations
- ACEs
Adverse Childhood Experiences
- ASD
Autism Spectrum Disorders
- BPA
Bisphenol A
- BPD
Borderline Personality Disorder
- DNMT
DNA methyltransferases
- DOHaD
Developmental Origins of Health and Disease
- EDCs
Endocrine Disrupting Chemicals
- GAD
generalized anxiety disorder
- MDD
major depressive disorder
- MHD
mental health disorder
- OCD
obsessive-compulsive disorder
- POP
Persistent Organic Pollutants
- PTSD
post-traumatic stress disorder
Contributor Information
Micah Allen, Email: micahpjallen@gmail.com.
Carlos Guerrero-Bosagna, Email: carlos.guerrero.bosagna@ebc.uu.se.
Competing Interests
The authors declare that there are no competing interests associated with the manuscript.
Funding
C.G.B. appreciates funding by FORMAS [Grant #2021-00532].
Open Access
This article has been published open access under our Subscribe to Open programme, made possible through the support of our subscribing institutions, learn more here: https://portlandpress.com/pages/open_access_options_and_prices#conditional
CRediT Author Contribution
M.A.: Writing–original draft. C.G.B.: Writing–review & editing.
References
- 1. Wu Y., Wang L., Tao M., Cao H., Yuan H., Ye M., et al. Changing trends in the global burden of mental disorders from 1990 to 2019 and predicted levels in 25 years. Epidemiol. Psychiatr. Sci. 2023;32:e63. doi: 10.1017/S2045796023000756. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Mental health Mental health. 2025. https://www.who.int/health-topics/mental-health
- 3. Husky M.M., Alvarez Fernandez V., Tapia G., Oprescu F., Navarro-Mateu F., Kovess-Masfety V Mental disorders and medical conditions associated with causing injury or death: A population-based study. Psychiatry Res. 2020;287:112899. doi: 10.1016/j.psychres.2020.112899. [DOI] [PubMed] [Google Scholar]
- 4. Wu L.T., Kouzis A.C., Leaf P.J Influence of comorbid alcohol and psychiatric disorders on utilization of mental health services in the national comorbidity survey. AJP. 1999;156:1230–1236. doi: 10.1176/ajp.156.8.1230. [DOI] [PubMed] [Google Scholar]
- 5. McGrath J.J., Lim C.C.W., Plana-Ripoll O., Holtz Y., Agerbo E., Momen N.C., et al. Comorbidity within mental disorders: a comprehensive analysis based on 145 990 survey respondents from 27 countries. Epidemiol. Psychiatr. Sci. 2020;29:e153. doi: 10.1017/S2045796020000633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Al-Asadi A.M., Klein B., Meyer D Multiple comorbidities of 21 psychological disorders and relationships with psychosocial variables: a study of the online assessment and diagnostic system within a web-based population. J. Med. Internet Res. 2015;17:e55. doi: 10.2196/jmir.4143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Zbozinek T.D., Rose R.D., Wolitzky-Taylor K.B., Sherbourne C., Sullivan G., Stein M.B., et al. Diagnostic overlap of generalized anxiety disorder and major depressive disorder in a primary care sample. Depress. Anxiety. 2012;29:1065–1071. doi: 10.1002/da.22026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Fava M., Alpert J.E., Carmin C.N., Wisniewski S.R., Trivedi M.H., Biggs M.M., et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol. Med. 2004;34:1299–1308. doi: 10.1017/s0033291704002612. [DOI] [PubMed] [Google Scholar]
- 9. Uher R., Zwicker A Etiology in psychiatry: embracing the reality of poly-gene-environmental causation of mental illness. World Psychiatry. 2017;16:121–129. doi: 10.1002/wps.20436. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Polderman T.J.C., Benyamin B., De Leeuw C.A., Sullivan P.F., Van Bochoven A., Visscher P.M, et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. Nat. Genet. 2015;47:702–709. doi: 10.1038/ng.3285. [DOI] [PubMed] [Google Scholar]
- 11. Andreassen O.A., Hindley G.F.L., Frei O., Smeland OB New insights from the last decade of research in psychiatric genetics: discoveries, challenges and clinical implications. World Psychiatry. 2023;22:4–24. doi: 10.1002/wps.21034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Reiss F., Meyrose A.-K., Otto C., Lampert T., Klasen F., Ravens-Sieberer U Socioeconomic status, stressful life situations and mental health problems in children and adolescents: Results of the German BELLA cohort-study. PLoS ONE. 2019;14:e0213700. doi: 10.1371/journal.pone.0213700. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Grezenko H., Ekhator C., Nwabugwu N.U., Ganga H., Affaf M., Abdelaziz A.M., et al. Epigenetics in neurological and psychiatric disorders: a comprehensive review of current understanding and future perspectives. Cureus. 2023;15:e43960. doi: 10.7759/cureus.43960. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Alavian-Ghavanini A., Rüegg J Understanding epigenetic effects of endocrine disrupting chemicals: from mechanisms to novel test methods. Basic Clin. Pharmacol. Toxicol. 2018;122:38–45. doi: 10.1111/bcpt.12878. [DOI] [PubMed] [Google Scholar]
- 15. Hagemann E., Silva D.T., Davis J.A., Gibson L.Y., Prescott S.L Developmental origins of health and disease (DOHaD): the importance of life-course and transgenerational approaches. Paediatr. Respir. Rev. 2021;40:3–9. doi: 10.1016/j.prrv.2021.05.005. [DOI] [PubMed] [Google Scholar]
- 16. Chapman D.P., Whitfield C.L., Felitti V.J., Dube S.R., Edwards V.J., Anda R.F Adverse childhood experiences and the risk of depressive disorders in adulthood. J. Affect. Disord. 2004;82:217–225. doi: 10.1016/j.jad.2003.12.013. [DOI] [PubMed] [Google Scholar]
- 17. Dunn E.C., Nishimi K., Powers A., Bradley B Is developmental timing of trauma exposure associated with depressive and post-traumatic stress disorder symptoms in adulthood? J. Psychiatr. Res. 2017;84:119–127. doi: 10.1016/j.jpsychires.2016.09.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Jiang C., Jiang S Effects of adverse childhood experiences on late-life mental health: potential mechanisms based on a nationally representative survey in china. Arch. Gerontol. Geriatr. 2022;100:104648. doi: 10.1016/j.archger.2022.104648. [DOI] [PubMed] [Google Scholar]
- 19. Dube S.R., Anda R.F., Felitti V.J., Chapman D.P., Williamson D.F., Giles W.H Childhood abuse, household dysfunction, and the risk of attempted suicide throughout the life span: findings from the adverse childhood experiences study. JAMA. 2001;286:3089–3096. doi: 10.1001/jama.286.24.3089. [DOI] [PubMed] [Google Scholar]
- 20. Sidamon-Eristoff A.E., Cohodes E.M., Gee D.G., Peña C.J Trauma exposure and mental health outcomes among Central American and Mexican children held in immigration detention at the United States-Mexico border. Dev. Psychobiol. 2022;64:e22227. doi: 10.1002/dev.22227. [DOI] [PubMed] [Google Scholar]
- 21. Björkenstam E., Vinnerljung B., Hjern A Impact of childhood adversities on depression in early adulthood: a longitudinal cohort study of 478,141 individuals in sweden. J. Affect. Disord. 2017;223:95–100. doi: 10.1016/j.jad.2017.07.030. [DOI] [PubMed] [Google Scholar]
- 22. Wirback T., Möller J., Larsson J.-O., Galanti M.R., Engström K Social factors in childhood and risk of depressive symptoms among adolescents--a longitudinal study in Stockholm, Sweden. Int. J. Equity Health. 2014;13:96. doi: 10.1186/s12939-014-0096-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Rajalin M., Hirvikoski T., Renberg E.S., Åsberg M., Jokinen J Exposure to early life adversity and interpersonal functioning in attempted suicide. Front. Psychiatry. 2020;11:552514. doi: 10.3389/fpsyt.2020.552514. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Ceccarelli C., Prina E., Muneghina O., Jordans M., Barker E., Miller K., et al. Adverse childhood experiences and global mental health: avenues to reduce the burden of child and adolescent mental disorders. Epidemiol. Psychiatr. Sci. 2022;31:e75. doi: 10.1017/S2045796022000580. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Gladieux M., Gimness N., Rodriguez B., Liu J Adverse childhood experiences (ACEs) and environmental exposures on neurocognitive outcomes in children: empirical evidence, potential mechanisms, and implications. Toxics. 2023;11:259. doi: 10.3390/toxics11030259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Ottova V., Erhart M., Rajmil L., Dettenborn-Betz L., Ravens-Sieberer U Overweight and its impact on the health-related quality of life in children and adolescents: results from the European KIDSCREEN survey. Qual. Life Res. 2012;21:59–69. doi: 10.1007/s11136-011-9922-7. [DOI] [PubMed] [Google Scholar]
- 27. Russell-Mayhew S., McVey G., Bardick A., Ireland A Mental health, wellness, and childhood overweight/obesity. J. Obes. 2012;2012:281801. doi: 10.1155/2012/281801. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Förster L.-J., Vogel M., Stein R., Hilbert A., Breinker J.L., Böttcher M., et al. Mental health in children and adolescents with overweight or obesity. BMC Public Health. 2023;23:135. doi: 10.1186/s12889-023-15032-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Griffiths L.J., Parsons T.J., Hill A.J Self-esteem and quality of life in obese children and adolescents: a systematic review. Int. J. Pediatr. Obes. 2010;5:282–304. doi: 10.3109/17477160903473697. [DOI] [PubMed] [Google Scholar]
- 30. Braet C., Mervielde I., Vandereycken W Psychological aspects of childhood obesity: a controlled study in a clinical and nonclinical sample. J. Pediatr. Psychol. 1997;22:59–71. doi: 10.1093/jpepsy/22.1.59. [DOI] [PubMed] [Google Scholar]
- 31. De Beer M., Hofsteenge G.H., Koot H.M., Hirasing R.A., Delemarre-van de Waal H.A., Gemke R.J.B.J Health-related-quality-of-life in obese adolescents is decreased and inversely related to BMI. Acta Paediatr. 2007;96:710–714. doi: 10.1111/j.1651-2227.2007.00243.x. [DOI] [PubMed] [Google Scholar]
- 32. Vila G., Zipper E., Dabbas M., Bertrand C., Robert J.J., Ricour C., et al. Mental disorders in obese children and adolescents. Psychosom. Med. 2004;66:387–394. doi: 10.1097/01.psy.0000126201.12813.eb. [DOI] [PubMed] [Google Scholar]
- 33. Heindel J.J., Lustig R.H., Howard S., Corkey B.E Obesogens: a unifying theory for the global rise in obesity. Int. J. Obes. (Lond) 2024;48:449–460. doi: 10.1038/s41366-024-01460-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Heindel J.J., Howard S., Agay-Shay K., Arrebola J.P., Audouze K., Babin P.J, et al. Obesity II: establishing causal links between chemical exposures and obesity. Biochem. Pharmacol. 2022;199:115015. doi: 10.1016/j.bcp.2022.115015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Mohajer N., Du C.Y., Checkcinco C., Blumberg B Obesogens: how they are identified and molecular mechanisms underlying their action. Front. Endocrinol. (Lausanne) 2021;12:780888. doi: 10.3389/fendo.2021.780888. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Carlezon W.A., Konradi C Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology. 2004;47 Suppl 1:47–60. doi: 10.1016/j.neuropharm.2004.06.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Dreier J.W., Bjørk M.-H., Alvestad S., Gissler M., Igland J., Leinonen M.K., et al. Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders. JAMA Neurol. 2023;80:568–577. doi: 10.1001/jamaneurol.2023.0674. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Oei J.L Improving neurological and mental health outcomes for children with prenatal drug exposure. Semin. Fetal Neonatal Med. 2024;29:101557. doi: 10.1016/j.siny.2024.101557. [DOI] [PubMed] [Google Scholar]
- 39.Crocker N., Fryer S., Mattson S. Exposure to Teratogens as a Risk Factor for Psychopathology. Second. Child And Adolescent Psychopathology. Second. John Wiley & Sons, Inc; 2013. https://perpus.univpancasila.ac.id/repository/EBUPT180233.pdf#page=295 [Google Scholar]
- 40. James A.A., OShaughnessy KL Environmental chemical exposures and mental health outcomes in children: a narrative review of recent literature. Front. Toxicol. 2023;5:1290119. doi: 10.3389/ftox.2023.1290119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Pei J., Denys K., Hughes J., Rasmussen C Mental health issues in fetal alcohol spectrum disorder. J. Ment. Health. 2011;20:438–448. doi: 10.3109/09638237.2011.577113. [DOI] [PubMed] [Google Scholar]
- 42. Georgieff M.K., Tran P.V., Carlson E.S Atypical fetal development: Fetal alcohol syndrome, nutritional deprivation, teratogens, and risk for neurodevelopmental disorders and psychopathology. Dev. Psychopathol. 2018;30:1063–1086. doi: 10.1017/S0954579418000500. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Eriksson M., Larsson G., Zetterström R Abuse of alcohol, drugs and tobacco during pregnancy--consequences for the child. Paediatrician. 1979;8:228–242. [PubMed] [Google Scholar]
- 44. Dias B.G., Ressler K.J Parental olfactory experience influences behavior and neural structure in subsequent generations. Nat. Neurosci. 2014;17:89–96. doi: 10.1038/nn.3594. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Gapp K., Jawaid A., Sarkies P., Bohacek J., Pelczar P., Prados J., et al. Implication of sperm RNAs in transgenerational inheritance of the effects of early trauma in mice. Nat. Neurosci. 2014;17:667–669. doi: 10.1038/nn.3695. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Kumar M., Sarma D.K., Shubham S., Kumawat M., Verma V., Prakash A., et al. Environmental endocrine-disrupting chemical exposure: role in non-communicable diseases. Front. Public Health. 2020;8:553850. doi: 10.3389/fpubh.2020.553850. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Predieri B., Iughetti L., Bernasconi S., Street M.E Endocrine disrupting chemicals’ effects in children: what we know and what we need to learn? Int. J. Mol. Sci. 2022;23:11899. doi: 10.3390/ijms231911899. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Özel F., Rüegg J Exposure to endocrine-disrupting chemicals and implications for neurodevelopment. Dev. Med. Child Neurol. 2023;65:1005–1011. doi: 10.1111/dmcn.15551. [DOI] [PubMed] [Google Scholar]
- 49. Jacobs M.N., Marczylo E.L., Guerrero-Bosagna C., Rüegg J Marked for life: epigenetic effects of endocrine disrupting chemicals. Annu. Rev. Environ. Resour. 2017;42:105–160. doi: 10.1146/annurev-environ-102016-061111. [DOI] [Google Scholar]
- 50. Mnif W., Hassine A.I.H., Bouaziz A., Bartegi A., Thomas O., Roig B Effect of endocrine disruptor pesticides: a review. Int. J. Environ. Res. Public Health. 2011;8:2265–2303. doi: 10.3390/ijerph8062265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Raja G.L., Subhashree K.D., Kantayya K.E In utero exposure to endocrine disruptors and developmental neurotoxicity: Implications for behavioural and neurological disorders in adult life. Environ. Res. 2022;203:111829. doi: 10.1016/j.envres.2021.111829. [DOI] [PubMed] [Google Scholar]
- 52. Street M.E., Angelini S., Bernasconi S., Burgio E., Cassio A., Catellani C., et al. Current Knowledge on Endocrine Disrupting Chemicals (EDCs) from Animal Biology to Humans, from Pregnancy to Adulthood: Highlights from a National Italian Meeting. Int. J. Mol. Sci. 2018;19:1647. doi: 10.3390/ijms19061647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Streifer M., Gore A.C Epigenetics, estrogenic endocrine-disrupting chemicals (EDCs), and the brain. Adv. Pharmacol. 2021;92:73–99. doi: 10.1016/bs.apha.2021.03.006. [DOI] [PubMed] [Google Scholar]
- 54. Kahn L.G., Philippat C., Nakayama S.F., Slama R., Trasande L Endocrine-disrupting chemicals: implications for human health. Lancet Diabetes Endocrinol. 2020;8:703–718. doi: 10.1016/S2213-8587(20)30129-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Segovia-Mendoza M., Palacios-Arreola M.I., Pavón L., Becerril L.E., Nava-Castro K.E., Amador-Muñoz O., et al. Environmental pollution to blame for depressive disorder? Int. J. Environ. Res. Public Health. 2022;19:1737. doi: 10.3390/ijerph19031737. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Palanza P., Gioiosa L., Vom Saal F.S., Parmigiani S Effects of developmental exposure to bisphenol A on brain and behavior in mice. Environ. Res. 2008;108:150–157. doi: 10.1016/j.envres.2008.07.023. [DOI] [PubMed] [Google Scholar]
- 57. Nagel S.C., Parmigiani S., Vom Saal F.S Perinatal exposure to endocrine disruptors: sex, timing and behavioral endpoints. Curr. Opin. Behav. Sci. 2016;7:69–75. doi: 10.1016/j.cobeha.2015.11.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Patisaul HB 2024. Dirty Minds: How Endocrine Disrupting Chemicals (EDCs) and Other Pollutants Affect the Neuroendocrinology of Behavior and Emotions In Neuroendocrinology of Behavior and Emotions: Environmental and Social Factors Affecting Behavior (Caldwell H.K., Albers H.E. eds pp 217 249 Springer International Publishing; 10.1007/978-3-031-51112-7_9 [DOI] [Google Scholar]
- 59. Kajta M., Wójtowicz AK Impact of endocrine-disrupting chemicals on neural development and the onset of neurological disorders. Pharmacol. Rep. 2013;65:1632–1639. doi: 10.1016/s1734-1140(13)71524-x. [DOI] [PubMed] [Google Scholar]
- 60. Aljabali A.A.A., Alkaraki A.K., Gammoh O., Tambuwala M.M., Mishra V., Mishra Y., et al. Deciphering depression: epigenetic mechanisms and treatment strategies. Biology (Basel) 2024;13:638. doi: 10.3390/biology13080638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Chen W.-Q., Yuan L., Xue R., Li Y.F., Su R.B., Zhang Y.Z., et al. Repeated exposure to chlorpyrifos alters the performance of adolescent male rats in animal models of depression and anxiety. Neurotoxicology. 2011;32:355–361. doi: 10.1016/j.neuro.2011.03.008. [DOI] [PubMed] [Google Scholar]
- 62. Kundakovic M., Gudsnuk K., Franks B., Madrid J., Miller R.L., Perera F.P., et al. Sex-specific epigenetic disruption and behavioral changes following low-dose in utero bisphenol A exposure. Proc. Natl. Acad. Sci. U.S.A. 2013;110:9956–9961. doi: 10.1073/pnas.1214056110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Akanbi C.A., Rotimi D.E., Ojo A.B., Ojo O.A Endocrine-disrupting chemicals (EDCs) and epigenetic regulation in embryonic development: Mechanisms, impacts, and emerging trends. Toxicol. Rep. 2025;14:101885. doi: 10.1016/j.toxrep.2024.101885. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Derghal A., Djelloul M., Trouslard J., Mounien L An emerging role of micro-RNA in the Effect of the endocrine disruptors. Front. Neurosci. 2016;10:318. doi: 10.3389/fnins.2016.00318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Kim K The role of endocrine disruption chemical-regulated aryl hydrocarbon receptor activity in the pathogenesis of pancreatic diseases and cancer. Int. J. Mol. Sci. 2024;25:3818. doi: 10.3390/ijms25073818. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Zhang W., Xie H.Q., Li Y., Zhou M., Zhou Z., Wang R., et al. The aryl hydrocarbon receptor: A predominant mediator for the toxicity of emerging dioxin-like compounds. J. Hazard. Mater. 2022;426:128084. doi: 10.1016/j.jhazmat.2021.128084. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Bock K.W Aryl hydrocarbon receptor (AHR)-mediated inflammation and resolution: Non-genomic and genomic signaling. Biochem. Pharmacol. 2020;182:114220. doi: 10.1016/j.bcp.2020.114220. [DOI] [PubMed] [Google Scholar]
- 68. Mackenzie Ross S.J., Brewin C.R., Curran H.V., Furlong C.E., Abraham-Smith K.M., Harrison V Neuropsychological and psychiatric functioning in sheep farmers exposed to low levels of organophosphate pesticides. Neurotoxicol. Teratol. 2010;32:452–459. doi: 10.1016/j.ntt.2010.03.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Walker D.M., Gore A.C Epigenetic impacts of endocrine disruptors in the brain. Front. Neuroendocrinol. 2017;44:1–26. doi: 10.1016/j.yfrne.2016.09.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Devi C.B., Reddy G.H., Prasanthi R.P.J., Chetty C.S., Reddy GR Developmental lead exposure alters mitochondrial monoamine oxidase and synaptosomal catecholamine levels in rat brain. Int. J. Dev. Neurosci. 2005;23:375–381. doi: 10.1016/j.ijdevneu.2004.11.003. [DOI] [PubMed] [Google Scholar]
- 71. Roy B., Dunbar M., Agrawal J., Allen L., Dwivedi Y Amygdala-Based Altered miRNome and Epigenetic Contribution of miR-128-3p in Conferring Susceptibility to Depression-Like Behavior via Wnt Signaling. Int. J. Neuropsychopharmacol. 2020;23:165–177. doi: 10.1093/ijnp/pyz071. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72. Perera F.P., Rauh V., Whyatt R.M., Tsai W.-Y., Tang D., Diaz D., et al. Effect of Prenatal exposure to airborne polycyclic aromatic hydrocarbonson neurodevelopment in the first 3 years of life among inner-city children. Environ. Health Perspect. 2006;114:1287–1292. doi: 10.1289/ehp.9084. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Edwards S.C., Jedrychowski W., Butscher M., Camann D., Kieltyka A., Mroz E., et al. Prenatal exposure to airborne polycyclic aromatic hydrocarbons and children’s intelligence at 5 years of age in a prospective cohort study in Poland. Environ. Health Perspect. 2010;118:1326–1331. doi: 10.1289/ehp.0901070. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74. Fitsanakis V.A., Au C., Erikson K.M., Aschner M The effects of manganese on glutamate, dopamine and gamma-aminobutyric acid regulation. Neurochem. Int. 2006;48:426–433. doi: 10.1016/j.neuint.2005.10.012. [DOI] [PubMed] [Google Scholar]
- 75. Suzuki T., Mizuo K., Nakazawa H., Funae Y., Fushiki S., Fukushima S., et al. Prenatal and neonatal exposure to bisphenol-A enhances the central dopamine D1 receptor-mediated action in mice: enhancement of the methamphetamine-induced abuse state. Neuroscience. 2003;117:639–644. doi: 10.1016/s0306-4522(02)00935-1. [DOI] [PubMed] [Google Scholar]
- 76. Masuo Y., Ishido M Neurotoxicity of endocrine disruptors: possible involvement in brain development and neurodegeneration. J. Toxicol. Environ. Health B. Crit. Rev. 2011;14:346–369. doi: 10.1080/10937404.2011.578557. [DOI] [PubMed] [Google Scholar]
- 77. Rauh V.A., Margolis A.E Research Review: Environmental exposures, neurodevelopment, and child mental health – new paradigms for the study of brain and behavioral effects. Child Psychology Psychiatry. 2016;57:775–793. doi: 10.1111/jcpp.12537. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78. Hou L., Zhang X., Wang D., Baccarelli A Environmental chemical exposures and human epigenetics. Int. J. Epidemiol. 2012;41:79–105. doi: 10.1093/ije/dyr154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79. Zhang L., Wang Z., Liu K., Li J., Li Y Investigation of the relationship between heavy metals in the blood and depression in people with different body mass indices using the NHANES database: A cross-sectional study. J. Affect. Disord. 2024;344:311–318. doi: 10.1016/j.jad.2023.10.023. [DOI] [PubMed] [Google Scholar]
- 80. Orisakwe O.E The role of lead and cadmium in psychiatry. N. Am. J. Med. Sci. 2014;6:370–376. doi: 10.4103/1947-2714.139283. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81. Pemberton R., Fuller Tyszkiewicz M.D Factors contributing to depressive mood states in everyday life: A systematic review. J. Affect. Disord. 2016;200:103–110. doi: 10.1016/j.jad.2016.04.023. [DOI] [PubMed] [Google Scholar]
- 82. Koller K., Brown T., Spurgeon A., Levy L Recent developments in low-level lead exposure and intellectual impairment in children. Environ. Health Perspect. 2004;112:987–994. doi: 10.1289/ehp.6941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83. Gump B.B., Dykas M.J., MacKenzie J.A., Dumas A.K., Hruska B., Ewart C.K, et al. Background lead and mercury exposures: psychological and behavioral problems in children. Environ. Res. 2017;158:576–582. doi: 10.1016/j.envres.2017.06.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84. Zeng X., Xu C., Xu X., Zhang Y., Huang Y., Huo X Elevated lead levels in relation to low serum neuropeptide Y and adverse behavioral effects in preschool children with e-waste exposure. Chemosphere. 2021;269 doi: 10.1016/j.chemosphere.2020.129380. [DOI] [PubMed] [Google Scholar]
- 85. Wegmann B., Tatemoto P., Miemczyk S., Ludvigsson J., Guerrero-Bosagna C Identification of potentially relevant metals for the etiology of autism by using a Bayesian multivariate approach for partially censored values. Sci. Rep. 2023;13:12622. doi: 10.1038/s41598-023-38780-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86. Baccarelli A., Bollati V Epigenetics and environmental chemicals. Curr. Opin. Pediatr. 2009;21:243–251. doi: 10.1097/mop.0b013e32832925cc. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87. Martinez-Zamudio R., Ha H.C Environmental epigenetics in metal exposure. Epigenetics. 2011;6:820–827. doi: 10.4161/epi.6.7.16250. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88. Senut M.C., Cingolani P., Sen A., Kruger A., Shaik A., Hirsch H., et al. Epigenetics of early-life lead exposure and effects on brain development. Epigenomics. 2012;4:665–674. doi: 10.2217/epi.12.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89. Fragou D., Fragou A., Kouidou S., Njau S., Kovatsi L Epigenetic mechanisms in metal toxicity. Toxicol. Mech. Methods. 2011;21:343–352. doi: 10.3109/15376516.2011.557878. [DOI] [PubMed] [Google Scholar]
- 90. Zeng Z., Huo X., Zhang Y., Hylkema M.N., Wu Y., Xu X Differential DNA methylation in newborns with maternal exposure to heavy metals from an e-waste recycling area. Environ. Res. 2019;171:536–545. doi: 10.1016/j.envres.2019.01.007. [DOI] [PubMed] [Google Scholar]
- 91. Horvath S DNA methylation age of human tissues and cell types. Genome Biol. 2013;14:3156. R115. doi: 10.1186/gb-2013-14-10-r115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92. Dhingra R., Nwanaji-Enwerem J.C., Samet M., Ward-Caviness CK DNA Methylation Age-environmental influences, health impacts, and its role in environmental epidemiology. Curr. Environ. Health Rep. 2018;5:317–327. doi: 10.1007/s40572-018-0203-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93. Van der Laan L., Cardenas A., Vermeulen R., Fadadu R.P., Hubbard A.E., Phillips R.V, et al. Epigenetic aging biomarkers and occupational exposure to benzene, trichloroethylene and formaldehyde. Environ. Int. 2022;158:106871. doi: 10.1016/j.envint.2021.106871. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94. Ringrose L., Paro R Remembering silence. Bioessays. 2001;23:566–570. doi: 10.1002/bies.1082. [DOI] [PubMed] [Google Scholar]
- 95. Sales A.J., Biojone C., Terceti M.S., Guimarães F.S., Gomes M.V., Joca SR Antidepressant‐like effect induced by systemic and intra‐hippocampal administration of DNA methylation inhibitors. Br. J. Pharmacol. 2011;164:1711–1721. doi: 10.1111/j.1476-5381.2011.01489.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96. Shi Y.G., Tsukada Y The discovery of histone demethylases. Cold Spring Harb. Perspect. Biol. 2013;5:a017947. doi: 10.1101/cshperspect.a017947. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97. Xu J., Andreassi M Reversible histone methylation regulates brain gene expression and behavior. Horm. Behav. 2011;59:383–392. doi: 10.1016/j.yhbeh.2010.08.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98. Chen Z.J., Tian L Roles of dynamic and reversible histone acetylation in plant development and polyploidy. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 2007;1769:295–307. doi: 10.1016/j.bbaexp.2007.04.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99. Dugué P.-A., Jung C.-H., Joo J.E., Wang X., Wong E.M., Makalic E., et al. Smoking and blood DNA methylation: an epigenome-wide association study and assessment of reversibility. Epigenetics. 2020;15:358–368. doi: 10.1080/15592294.2019.1668739. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100. Weaver I.C.G., Cervoni N., Champagne F.A., D’Alessio A.C., Sharma S., Seckl J.R., et al. Epigenetic programming by maternal behavior. Nat. Neurosci. 2004;7:847–854. doi: 10.1038/nn1276. [DOI] [PubMed] [Google Scholar]
- 101. Albert P.R Epigenetics in mental illness: hope or hype? J. Psychiatry Neurosci. 2010;35:366–368. doi: 10.1503/jpn.100148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102. Kripalani S., Pradhan B., Gilrain K.L The potential positive epigenetic effects of various mind-body therapies (MBTs): a narrative review. J. Complement. Integr. Med. 2022;19:827–832. doi: 10.1515/jcim-2021-0039. [DOI] [PubMed] [Google Scholar]
- 103. Kaliman P., Cosín-Tomás M., Madrid A., Roque López S., Llanez-Anaya E., Papale L.A., et al. Epigenetic impact of a 1-week intensive multimodal group program for adolescents with multiple adverse childhood experiences. Sci. Rep. 2022;12:17177. doi: 10.1038/s41598-022-21246-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104. Covington H.E. 3rd, Maze I., LaPlant Q.C., Vialou V.F., Ohnishi Y.N., Berton O., et al. Antidepressant actions of histone deacetylase inhibitors. J. Neurosci. 2009;29:11451–11460. doi: 10.1523/JNEUROSCI.1758-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105. Toth M Epigenetic neuropharmacology: drugs affecting the epigenome in the brain. Annu. Rev. Pharmacol. Toxicol. 2021;61:181–201. doi: 10.1146/annurev-pharmtox-030220-022920. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106. Falahi F., Van Kruchten M., Martinet N., Hospers G.A.P., Rots M.G Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. Breast Cancer Res. 2014;16:412. doi: 10.1186/s13058-014-0412-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107. Gladkova M.G., Leidmaa E., Anderzhanova E.A Epidrugs in the therapy of central nervous system disorders: a way to drive on? Cells. 2023;12:1464. doi: 10.3390/cells12111464. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108. Czarny P., Białek K., Ziółkowska S., Strycharz J., Barszczewska G., Sliwinski T The importance of epigenetics in diagnostics and treatment of major depressive disorder. J. Pers. Med. 2021;11:167. doi: 10.3390/jpm11030167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109. Singh D., Khan M.A., Siddique H.R Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements. Epigenomics. 2023;15:517–537. doi: 10.2217/epi-2023-0142. [DOI] [PubMed] [Google Scholar]
- 110. Suraweera A., O’Byrne K.J., Richard DJ Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025;44:37. doi: 10.1007/s10555-025-10253-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111. Cossío F.P., Esteller M., Berdasco M Towards a more precise therapy in cancer: Exploring epigenetic complexity. Curr. Opin. Chem. Biol. 2020;57:41–49. doi: 10.1016/j.cbpa.2020.04.008. [DOI] [PubMed] [Google Scholar]
- 112. Nie J., Liu L., Li X., Han W Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. Cancer Lett. 2014;354:12–20. doi: 10.1016/j.canlet.2014.08.010. [DOI] [PubMed] [Google Scholar]
- 113. Robison S.K The political implications of epigenetics: emerging narratives and ideologies. Polit Life Sci. 2016;35:30–53. doi: 10.1017/pls.2016.14. [DOI] [PubMed] [Google Scholar]
- 114. Park C., Rosenblat J.D., Brietzke E., Pan Z., Lee Y., Cao B, et al. Stress, epigenetics and depression: a systematic review. Neurosci. Biobehav. Rev. 2019;102:139–152. doi: 10.1016/j.neubiorev.2019.04.010. [DOI] [PubMed] [Google Scholar]

